MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
– New Chemical Entity Aims to Provide New Treatments for Refractory Depression and Depression with Suicidal Thoughts – – Ketamir-2 Is Being Developed As a Take Home Alternative to The...
Adam Kaplin Erez Aminov Johns Hopkins Esketamine Johns Hopkins Drug Administration Pharmaceuticals Inc
Source: marketscreener.com